STOCK TITAN

[Form 4] SANGAMO THERAPEUTICS, INC Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Sangamo Therapeutics (SGMO) officer files Form 4 disclosing a tax-withholding transaction tied to RSU vesting. On 10/22/2025, the Principal Financial Officer surrendered 45,225 shares at $0.66 per share under transaction code F, which reflects shares withheld for taxes, not an open‑market sale.

Following the transaction, the officer beneficially owned 699,262 shares. The filing notes RSU activity and schedules: 43,837 shares vested on 10/22/2025 from a 1/22/2024 grant, with 89,063 shares scheduled to vest in equal quarterly installments through 1/22/2026; 10,020 shares from a 2/24/2023 grant vest in equal quarterly installments through 2/24/2026; and 120,000 shares from a 2/25/2025 grant vest 1/4 on 2/25/2026 and the balance in eight successive equal quarterly installments thereafter, subject to continuous service and potential acceleration under the company’s 2018 Equity Incentive Plan.

Funzionario di Sangamo Therapeutics (SGMO) presenta il modulo 4 e rivela una transazione di trattenuta fiscale legata al vesting di RSU. Il 22/10/2025, il Responsabile Finanziario e Vicedirettore ha rinunciato a 45.225 azioni a 0,66 USD ciascuna, secondo il codice di transazione F, che riflette azioni trattenute per le tasse e non una vendita sul mercato aperto.

Dopo la transazione, l'ufficiale possedeva in modo beneficiario 699.262 azioni. La compilazione nota l'attività RSU e i calendari: 43.837 azioni vestite il 22/10/2025 derivanti dall'assegnazione del 22/01/2024, con 89.063 azioni previste per vestire in rate trimestrali uguali fino al 22/01/2026; 10.020 azioni dell'assegnazione del 24/02/2023 vestono in rate trimestrali uguali fino al 24/02/2026; e 120.000 azioni dell'assegnazione del 25/02/2025 vestono 1/4 il 25/02/2026 e il saldo nelle otto rate trimestrali successive, soggetto a servizio continuo e possibile accelerazione ai sensi del Piano di Incentivi Azionari 2018 dell'azienda.

Los oficiales de Sangamo Therapeutics (SGMO) presentan el Formulario 4 divulgando una transacción de retención de impuestos vinculada al vesting de RSU. El 22/10/2025, el Director Financiero Principal entregó 45,225 acciones a 0,66 USD por acción bajo el código de transacción F, que refleja acciones retenidas para impuestos y no una venta en el mercado abierto.

Después de la transacción, el directivo pasó a poseer 699,262 acciones de forma beneficiosa. La presentación señala la actividad y el calendario de RSU: 43,837 acciones vestidas el 22/10/2025 a partir de una adjudicación del 22/01/2024, con 89,063 acciones previstas para vesting en cuotas trimestrales iguales hasta el 22/01/2026; 10,020 acciones de una adjudicación del 24/02/2023 vest en cuotas trimestrales iguales hasta el 24/02/2026; y 120,000 acciones de una adjudicación del 25/02/2025 vesting 1/4 el 25/02/2026 y el saldo en ocho cuotas trimestrales sucesivas, sujeto a servicio continuo y posible aceleración bajo el Plan de Incentivos de Acciones 2018 de la empresa.

상가모 테라퓨틱스(SGMO) 임원이 Form 4를 제출하여 RSU 가상속권의 귀속과 관련된 세금 원천징수 거래를 공시합니다. 2025년 10월 22일, 주요 재무 담당 임원은 거래 코드 F에 따라 주당 0.66달러로 45,225주를 넘겼으며, 이는 세금을 위한 보유 주식으로, 열린 시장에서의 매도가 아님을 반영합니다.

거래 후 해당 임원은 양도된 주식을 포함해 699,262주를 실제로 소유하게 되었습니다. 공시에는 RSU 활동 및 일정이 명시되어 있습니다: 2025년 10월 22일에 귀속된 43,837주가 2024년 1월 22일의 부여에서 발생했고, 89,063주는 2026년 1월 22일까지 분기별로 동등하게 귀속될 예정입니다; 2023년 2월 24일 부여의 10,020주는 2026년 2월 24일까지 분기별로 동등하게 귀속됩니다; 2025년 2월 25일 부여의 120,000주는 2026년 2월 25일 1/4 귀속으로 시작하고, 이후 지속적으로 동일한 분기별로 8회에 걸쳐 귀속되며, 지속적 근무와 회사의 2018년 주식 인센티브 계획에 따른 가속화 가능성에 따릅니다.

Un cadre de Sangamo Therapeutics (SGMO) dépose le Formulaire 4 révélant une opération de retenue d'impôt liée au vesting des RSU. Le 22/10/2025, le Directeur Financier Principal a cédé 45 225 actions à 0,66 USD par action dans le cadre du code de transaction F, reflétant des actions retenues pour les impôts et non une vente sur le marché.

Suite à l'opération, le cadre détenait bénéficiairement 699 262 actions. Le dépôt indique l'activité RSU et les plannings: 43 837 actions vestées le 22/10/2025 à partir d'une attribution du 22/01/2024, avec 89 063 actions prévues pour vesting par tranches trimestrielles égales jusqu'au 22/01/2026; 10 020 actions d'une attribution du 24/02/2023 vestent par tranches trimestrielles égales jusqu'au 24/02/2026; et 120 000 actions d'une attribution du 25/02/2025 vestent à 1/4 le 25/02/2026 et le solde en huit tranches trimestrielles égales successives, sous réserve d'un service continu et d'une éventuelle accélération selon le Plan d'Incitation en Actions 2018 de l'entreprise.

Ein Beauftragter von Sangamo Therapeutics (SGMO) reicht Formular 4 ein und veröffentlicht eine steuerabzugsbedingte Transaktion, die mit RSU-Vestings zusammenhängt. Am 22.10.2025 trat der Chief Financial Officer eine Aktie 45.225 zu 0,66 USD pro Aktie unter dem Transaktionscode F ab, was Aktien zeigt, die zur Begleichung von Steuern einbehalten wurden und kein Verkauf am freien Markt ist.

Nach der Transaktion besaß der Beauftragte vorteilhaft 699.262 Aktien. Die Einreichung notiert RSU-Aktivitäten und Zeitpläne: 43.837 Aktien vesteten am 22.10.2025 aus einer Zuteilung vom 22.01.2024, wobei 89.063 Aktien voraussichtlich in gleichen vierteljährlichen Raten bis zum 22.01.2026 vesten werden; 10.020 Aktien aus einer Zuteilung vom 24.02.2023 vesten in gleichen vierteljährlichen Raten bis zum 24.02.2026; und 120.000 Aktien aus einer Zuteilung vom 25.02.2025 vesten am 25.02.2026 zu einem Viertel und der Rest in acht aufeinanderfolgenden gleichen vierteljährlichen Raten, vorbehaltlich kontinuierlicher Dienste und möglicher Beschleunigung gemäß dem Equity Incentive Plan 2018 des Unternehmens.

قام موظف في Sangamo Therapeutics (SGMO) بتقديم النموذج 4 وكشف عن صفقة حجز ضرائب مرتبطة بتجسيد RSU. في 22/10/2025 تخلى كبير موظفي الشؤون المالية عن 45,225 سهماً بسعر 0.66 دولار للسهم وفق رمز الصفقة F، وهو ما يعكس أسهماً محجوبة للضرائب وليست بيعاً في السوق المفتوح.

بعد الصفقة، كان لدى الموظف 699,262 سهماً بشكل فعّال. تذكر الإيداع نشاط RSU والجداول الزمنية: 43,837 سهماً جرى التجند بها في 22/10/2025 من منحة 22/01/2024، مع تقدم 89,063 سهماً ليتم vesting بها بنسب ربع سنوية متساوية حتى 22/01/2026؛ 10,020 سهماً من منحة 24/02/2023 vest بنسب ربع سنوية متساوية حتى 24/02/2026؛ و120,000 سهماً من منحة 25/02/2025 vest بمقدار ربع واحد في 25/02/2026 والباقي في ثمانية دفعات ربع سنوية متتالية، رهناً بالخدمة المستمرة وإمكانية التسريع وفقاً لخطة الحوافز بالأسهم لعام 2018 للشركة.

Positive
  • None.
Negative
  • None.

Funzionario di Sangamo Therapeutics (SGMO) presenta il modulo 4 e rivela una transazione di trattenuta fiscale legata al vesting di RSU. Il 22/10/2025, il Responsabile Finanziario e Vicedirettore ha rinunciato a 45.225 azioni a 0,66 USD ciascuna, secondo il codice di transazione F, che riflette azioni trattenute per le tasse e non una vendita sul mercato aperto.

Dopo la transazione, l'ufficiale possedeva in modo beneficiario 699.262 azioni. La compilazione nota l'attività RSU e i calendari: 43.837 azioni vestite il 22/10/2025 derivanti dall'assegnazione del 22/01/2024, con 89.063 azioni previste per vestire in rate trimestrali uguali fino al 22/01/2026; 10.020 azioni dell'assegnazione del 24/02/2023 vestono in rate trimestrali uguali fino al 24/02/2026; e 120.000 azioni dell'assegnazione del 25/02/2025 vestono 1/4 il 25/02/2026 e il saldo nelle otto rate trimestrali successive, soggetto a servizio continuo e possibile accelerazione ai sensi del Piano di Incentivi Azionari 2018 dell'azienda.

Los oficiales de Sangamo Therapeutics (SGMO) presentan el Formulario 4 divulgando una transacción de retención de impuestos vinculada al vesting de RSU. El 22/10/2025, el Director Financiero Principal entregó 45,225 acciones a 0,66 USD por acción bajo el código de transacción F, que refleja acciones retenidas para impuestos y no una venta en el mercado abierto.

Después de la transacción, el directivo pasó a poseer 699,262 acciones de forma beneficiosa. La presentación señala la actividad y el calendario de RSU: 43,837 acciones vestidas el 22/10/2025 a partir de una adjudicación del 22/01/2024, con 89,063 acciones previstas para vesting en cuotas trimestrales iguales hasta el 22/01/2026; 10,020 acciones de una adjudicación del 24/02/2023 vest en cuotas trimestrales iguales hasta el 24/02/2026; y 120,000 acciones de una adjudicación del 25/02/2025 vesting 1/4 el 25/02/2026 y el saldo en ocho cuotas trimestrales sucesivas, sujeto a servicio continuo y posible aceleración bajo el Plan de Incentivos de Acciones 2018 de la empresa.

상가모 테라퓨틱스(SGMO) 임원이 Form 4를 제출하여 RSU 가상속권의 귀속과 관련된 세금 원천징수 거래를 공시합니다. 2025년 10월 22일, 주요 재무 담당 임원은 거래 코드 F에 따라 주당 0.66달러로 45,225주를 넘겼으며, 이는 세금을 위한 보유 주식으로, 열린 시장에서의 매도가 아님을 반영합니다.

거래 후 해당 임원은 양도된 주식을 포함해 699,262주를 실제로 소유하게 되었습니다. 공시에는 RSU 활동 및 일정이 명시되어 있습니다: 2025년 10월 22일에 귀속된 43,837주가 2024년 1월 22일의 부여에서 발생했고, 89,063주는 2026년 1월 22일까지 분기별로 동등하게 귀속될 예정입니다; 2023년 2월 24일 부여의 10,020주는 2026년 2월 24일까지 분기별로 동등하게 귀속됩니다; 2025년 2월 25일 부여의 120,000주는 2026년 2월 25일 1/4 귀속으로 시작하고, 이후 지속적으로 동일한 분기별로 8회에 걸쳐 귀속되며, 지속적 근무와 회사의 2018년 주식 인센티브 계획에 따른 가속화 가능성에 따릅니다.

Un cadre de Sangamo Therapeutics (SGMO) dépose le Formulaire 4 révélant une opération de retenue d'impôt liée au vesting des RSU. Le 22/10/2025, le Directeur Financier Principal a cédé 45 225 actions à 0,66 USD par action dans le cadre du code de transaction F, reflétant des actions retenues pour les impôts et non une vente sur le marché.

Suite à l'opération, le cadre détenait bénéficiairement 699 262 actions. Le dépôt indique l'activité RSU et les plannings: 43 837 actions vestées le 22/10/2025 à partir d'une attribution du 22/01/2024, avec 89 063 actions prévues pour vesting par tranches trimestrielles égales jusqu'au 22/01/2026; 10 020 actions d'une attribution du 24/02/2023 vestent par tranches trimestrielles égales jusqu'au 24/02/2026; et 120 000 actions d'une attribution du 25/02/2025 vestent à 1/4 le 25/02/2026 et le solde en huit tranches trimestrielles égales successives, sous réserve d'un service continu et d'une éventuelle accélération selon le Plan d'Incitation en Actions 2018 de l'entreprise.

Ein Beauftragter von Sangamo Therapeutics (SGMO) reicht Formular 4 ein und veröffentlicht eine steuerabzugsbedingte Transaktion, die mit RSU-Vestings zusammenhängt. Am 22.10.2025 trat der Chief Financial Officer eine Aktie 45.225 zu 0,66 USD pro Aktie unter dem Transaktionscode F ab, was Aktien zeigt, die zur Begleichung von Steuern einbehalten wurden und kein Verkauf am freien Markt ist.

Nach der Transaktion besaß der Beauftragte vorteilhaft 699.262 Aktien. Die Einreichung notiert RSU-Aktivitäten und Zeitpläne: 43.837 Aktien vesteten am 22.10.2025 aus einer Zuteilung vom 22.01.2024, wobei 89.063 Aktien voraussichtlich in gleichen vierteljährlichen Raten bis zum 22.01.2026 vesten werden; 10.020 Aktien aus einer Zuteilung vom 24.02.2023 vesten in gleichen vierteljährlichen Raten bis zum 24.02.2026; und 120.000 Aktien aus einer Zuteilung vom 25.02.2025 vesten am 25.02.2026 zu einem Viertel und der Rest in acht aufeinanderfolgenden gleichen vierteljährlichen Raten, vorbehaltlich kontinuierlicher Dienste und möglicher Beschleunigung gemäß dem Equity Incentive Plan 2018 des Unternehmens.

قام موظف في Sangamo Therapeutics (SGMO) بتقديم النموذج 4 وكشف عن صفقة حجز ضرائب مرتبطة بتجسيد RSU. في 22/10/2025 تخلى كبير موظفي الشؤون المالية عن 45,225 سهماً بسعر 0.66 دولار للسهم وفق رمز الصفقة F، وهو ما يعكس أسهماً محجوبة للضرائب وليست بيعاً في السوق المفتوح.

بعد الصفقة، كان لدى الموظف 699,262 سهماً بشكل فعّال. تذكر الإيداع نشاط RSU والجداول الزمنية: 43,837 سهماً جرى التجند بها في 22/10/2025 من منحة 22/01/2024، مع تقدم 89,063 سهماً ليتم vesting بها بنسب ربع سنوية متساوية حتى 22/01/2026؛ 10,020 سهماً من منحة 24/02/2023 vest بنسب ربع سنوية متساوية حتى 24/02/2026؛ و120,000 سهماً من منحة 25/02/2025 vest بمقدار ربع واحد في 25/02/2026 والباقي في ثمانية دفعات ربع سنوية متتالية، رهناً بالخدمة المستمرة وإمكانية التسريع وفقاً لخطة الحوافز بالأسهم لعام 2018 للشركة.

Sangamo Therapeutics (SGMO) 的一名高管提交了 Form 4,披露与 RSU 授予归属相关的代扣税交易。 在 2025/10/22,首席财务官按交易代码 F 以每股 0.66 美元放弃 45,225 股,此举反映为税款而扣留的股份,并非在公开市场的出售。

交易完成后,该高管实际拥股份额为 699,262 股。申报中指出 RSU 活动和时间表:2025/10/22 从 2024/01/22 授予的 43,837 股已归属,预计 89,063 股将按季度等额归属,直至 2026/01/22;2023/02/24 授予的 10,020 股将按季度等额归属,至 2026/02/24;2025/02/25 授予的 120,000 股将于 2026/02/25 首次归属 1/4,余下部分随后在接下来的八个等额季度中归属,前提是持续任职,并可能根据公司 2018 年股权激励计划加速归属。

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Duraibabu Prathyusha

(Last) (First) (Middle)
C/O SANGAMO THERAPEUTICS, INC.
501 CANAL BLVD.

(Street)
RICHMOND CA 94084

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SANGAMO THERAPEUTICS, INC [ SGMO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
PRINCIPAL FINANCIAL OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
10/22/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/22/2025 F 45,225(1) D $0.66 699,262(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on October 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on October 22, 2025 of $0.66/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
2. Includes: (a) 43,837 shares resulting from the October 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 89,063 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 10,020 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
/s/ Scott Willoughby, Attorney-in-Fact 10/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Sangamo Therapeutics Inc

NASDAQ:SGMO

SGMO Rankings

SGMO Latest News

SGMO Latest SEC Filings

SGMO Stock Data

198.16M
294.97M
2.16%
16.96%
4.96%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
RICHMOND